Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2012

01-10-2012 | Research Article

Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors

Authors: Maroulio Talieri, Marita Zoma, Marina Devetzi, Andreas Scorilas, Alexandros Ardavanis

Published in: Tumor Biology | Issue 5/2012

Login to get access

Abstract

Kallikrein-related peptidases (KLKs) are emerging novel new biomarkers for prognosis, diagnosis and therapeutic intervention of cancer. Kallikrein-related peptidase 6 (KLK6) has the highest expression in normal brain among other tissues. Although its expression has been extensively studied in many types of cancer and in neurodegenerative diseases, very little is known for its expression in intracranial tumors. In the present study, 73 intracranial tumor samples were examined for KLK6 messenger ribunucleic acid (mRNA) gene expression using quantitative real-time polymerase chain reaction. Statistical analysis revealed the significant association of KLK6 expression with clinical and pathological parameters. Follow-up information was available for a median time of 20 months (range 1–59 months). KLK6 is expressed more frequently in tumors of high malignancy like the glioblastomas (70.6 %) and less in tumors of low malignancy like the meningiomas (12.5 %). KLK6 positive expression is associated with tumor grade (p < 0.001), malignancy status (p < 0.001), and tumor histologic type (p = 0.001). Cox proportional hazard regression model using univariate analysis revealed for the first time that positive KLK6 expression is a significant factor for disease-free survival (DFS; p = 0.041) of patients suffering from intracranial tumors. Kaplan–Meier survival curves demonstrated that negative KLK6 expression is significantly associated with longer DFS (p = 0.032). KLK6 gene expression may have clinical utility as a marker of unfavorable prognosis for intracranial tumors, and consequently, it could be used as target for therapeutic intervention.
Literature
1.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6–29.CrossRefPubMed
2.
3.
Davis F, Malmer B, Aldape K, Barnholtz-Sloan JS, Bondy ML, Brannstrom Th, et al. Issues of diagnostic review in brain tumor studies: From the brain tumor epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 2008;17:484–9.CrossRefPubMed
4.
Adamson C, Kanu OO, Mehta AI, Di CH, Lin N, Mattox AK, et al. Glioblastoma multiforme: A review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18:1061–83.CrossRefPubMed
5.
6.
Arribas Alpuente L, Menendez Lopez A, Yaya Tur R. Glioblastoma: Changing expectations. Clin Transl Oncol. 2011;13(4):240–8.CrossRefPubMed
7.
Claus EB, Bondy ML, Schildkraut JM, Wiemels J, Wrensch M, Black PΜ. Epidemiology of intra-cranial meningioma. Neurosurgery. 2005;57:1088–95.CrossRefPubMed
8.
Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010;99:379–91.CrossRefPubMed
9.
Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumor suppression. Nat Rev Cancer. 2007;7:800–8.CrossRefPubMed
10.
Borgono CA, Diamandis EP. The emerging roles of human kallikreins in cancer. Nat Rev Cancer. 2004;4:76–90.CrossRef
11.
Pampalakis G, Sotiropoulou G. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta. 2007;1776:22–31.PubMed
12.
Lu Y, Papagerakis P, Yamakoshi Y, Hu JCC, Bartlett JD, Simmer JP. Functions of KLK4 and MMP-20 in dental enamel formation. Biol Chem. 2008;389:695–700.CrossRefPubMedPubMedCentral
13.
Scarisbrick IA, Limbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegenaration. Biol Chem. 2008;389:739–46.CrossRefPubMedPubMedCentral
14.
Hollenberg MD, Oikonomopoulou K, Hansen KK, Saifeddine M, Ramachandran R, Diamandis EP. Kallikreins and proteinase-mediated signaling: Proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol Chem. 2008;389:643–51.CrossRefPubMed
15.
Shaw JLV, Diamandis EP. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology. Biol Chem. 2008;389:681–8.PubMed
16.
Smith RS, Gao Jr L, Chao L, Chao J. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008;389:725–30.CrossRefPubMed
17.
18.
Yousef GM, Tadaaki T. Diamandis EP (2003) Role of kallikrein enzymes in the central nervous system. Clin Chim Acta. 2003;329:1–8.CrossRefPubMed
19.
Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: Applications in cancer. Cancer Lett. 2005;224:1–22.CrossRefPubMed
20.
Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996;2:624–36.PubMedPubMedCentral
21.
Yamashiro K, Tsuruoka N, Kodama S, Tsujimoto M, Yamamura Y, Tanaka T, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta. 1997;1350(1):11–4.CrossRefPubMed
22.
Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer’s disease brain. J Biol Chem. 1997;272:25135–42.CrossRefPubMed
23.
Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP. Molecular characterization of zyme/protease M/neurosine (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics. 1999;62:251–9.CrossRefPubMed
24.
Bernett MJ, Blaber SI, Scarisbrick IA, Dhanaraja P, Thompson SM, Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem. 2002;277:24562–70.CrossRefPubMed
25.
Scarisbrick IA, Isackson PJ, Ciric B, Windebank AJ, Rodriguez M. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol. 2001;431:347–61.CrossRefPubMed
26.
Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53:1423–32.CrossRefPubMed
27.
Tatebea Η, Watanabeb Υ, Kasaia Τ, Mizunoa Τ, Nakagawaa Μ, Tanakab Μ, et al. Extracellular neurosin degrades α-synuclein in cultured cells. Neurosci Res. 2010;67:341–6.CrossRef
28.
Ashby EL, Kehoe PG, Love S. Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia. Brain Res. 2010;1363:1–10.CrossRefPubMed
29.
Scarisbrick IA, Blaber SI, Tingling JT, Rodriguez M, Blaber M, Christophi GP. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J Neuroimmunol. 2006;178:167–76.CrossRefPubMed
30.
Hebb AL, Bhan V, Wishart AD, Moore CS, Robertson GS. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. Curr Drug Discov Technol. 2010;7(2):137–40.CrossRefPubMed
31.
Mavridis K, Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol. 2010;6:269–85.CrossRefPubMed
32.
Shan SJ, Scorilas A, Katsaros D, Diamandis EP. Transcriptional up-regulation of human tissue kallikrein 6 in ovarian cancer: Clinical and mechanistic aspects. Br J Cancer. 2007;96:362–72.CrossRefPubMedPubMedCentral
33.
Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res. 2005;11:2889–93.CrossRefPubMed
34.
Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, et al. Clinicopathologic and biological significance of KLK6 overexpression in human gastric cancer. Clin Cancer Res. 2005;11:6800–6.CrossRefPubMed
35.
Ruckert F, Hennig M, Petraki CD, Wehrum D, Distler M, Denz A, et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. Br J Cancer. 2008;99(9):1484–92.CrossRefPubMedPubMedCentral
36.
\Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, et al. Human kallikrein 6: A new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 2005;11(9):3320–5.CrossRefPubMed
37.
Pampalakis G, Prosnikli E, Agalioti T, Vlahou A, Zoumpourlis V, Sotiropoulou G. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to mesenchymal transition. Cancer Res. 2009;69(9):3779–87.CrossRefPubMed
38.
Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP. Immunohistochemical localization of human kallikreins 6, 10, 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003;6(3):223–7.CrossRefPubMed
39.
Krenzer S, Peterziel H, Mauch C, Blaber SI, Blaber M, Angel P, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Invest Dermatol. 2011;131:2281–8.CrossRefPubMedPubMedCentral
40.
Ni X, Zhang W, Huabg KC, Wang Y, Ng SK, Mok SC, et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer. 2004;91(4):725–31.PubMedPubMedCentral
41.
Klucky B, Mueller R, Vogt I, Teurich S, Hartenstein B, Breuhahn K, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration and invasion. Cancer Res. 2007;67:8198–6.CrossRefPubMed
42.
Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, et al. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochim Biophys Res Commun. 2003;307:948–55.CrossRef
43.
Chosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumor cells. Tumor Biol. 2004;25:193–9.CrossRef
44.
Bayes A, Tseklenis T, Ventura S, Vendrell J, Aviles FX, Sotiropoulou G. Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation. Biol Chem. 2004;385:517–24.CrossRefPubMed
45.
Scarisbrick IA, Epstein B, Cloud BA, Yoon H, Wu J, Renner DN, et al. Functional role of kallikrein 6 in regulating immune cell survival. PLoS One. 2011;6(3):1–11. e18376.CrossRef
46.
Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res. 2009;29(8):3269–79.PubMed
47.
Prezas P, Scorilas A, Yfanti Ch, Viktorov P, Agnanti N, Diamandis EP, et al. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem. 2006;387:1607–12.PubMed
48.
Talieri M, Pappa E, Scorilas A, Devetzi M, Tsapralis N, Ardavanis A, et al. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. Tumor Biol. 2012. doi:10.​1007/​s13277-012-0347-x.
49.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMed
50.
Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMed
51.
Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, et al. The spectrum of human kallikrein6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem. 2001;49(11):1431–41.CrossRefPubMed
52.
Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol. 2002;103:351–5.CrossRefPubMed
53.
Klein R, Roggendorf W. Increased microglia proliferation separates pilocytic astrocytomas from diffuge astrocytomas: A double labeling study. Acta Neuropathol. 2001;101:245–8.PubMed
54.
Leenstra S, Das P, Troost D, Boer OJ, Bosch DA. Human malignant astrocytes express macrophage phenotype. J Neuroimmunol. 1995;56:17–25.CrossRefPubMed
Metadata
Title
Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors
Authors
Maroulio Talieri
Marita Zoma
Marina Devetzi
Andreas Scorilas
Alexandros Ardavanis
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0385-4

Other articles of this Issue 5/2012

Tumor Biology 5/2012 Go to the issue

Research Article

Acquired xanthine dehydrogenase expression shortens survival in patients with resected adenocarcinoma of lung

Research Article

HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma

Research Article

Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusion

Research Article

EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells

Research Article

CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-κB activation and NO production

Review

Environmental factors in causing human cancers: emphasis on tumorigenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits